Skip to Content

AdreView Approval History

FDA Approved: Yes (First approved September 19, 2008)
Brand name: AdreView
Generic name: iobenguane I 123
Dosage form: Injection
Company: GE Healthcare
Treatment for: Diagnosis and Investigation

AdreView is a diagnostic radiopharmaceutical agent indicated for use in the detection of rare neuroendocrine tumors in children and adults.

Development History and FDA Approval Process for AdreView

DateArticle
Sep 19, 2008Approval FDA Approves GE Healthcare's AdreView (Iobenguane I 123 Injection) Diagnostic Agent for Detecting Neuroendocrine Tumors in Children, Adults

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide